Kindstar Globalgene Technology, Inc.
HKEX:9960.HK
1.22 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 237.25 | 237.25 | 246.38 | 246.38 | 363.555 | 363.555 | 329.741 | 329.741 | 246.237 | 246.237 | 219.1 | 219.1 | 230.939 | 230.939 | 214.757 | 214.757 |
| Cost of Revenue
| 133.105 | 133.105 | 124.42 | 124.42 | 209.241 | 209.241 | 180.413 | 180.413 | 119.152 | 119.152 | 102.224 | 102.224 | 107.994 | 107.994 | 108.089 | 108.089 |
| Gross Profit
| 104.145 | 104.145 | 121.96 | 121.96 | 154.314 | 154.314 | 149.328 | 149.328 | 127.085 | 127.085 | 116.877 | 116.877 | 122.945 | 122.945 | 106.668 | 106.668 |
| Gross Profit Ratio
| 0.439 | 0.439 | 0.495 | 0.495 | 0.424 | 0.424 | 0.453 | 0.453 | 0.516 | 0.516 | 0.533 | 0.533 | 0.532 | 0.532 | 0.497 | 0.497 |
| Reseach & Development Expenses
| 26.277 | 26.277 | 26.392 | 26.392 | 28.233 | 28.233 | 22.38 | 22.38 | 23.983 | 23.983 | 21.18 | 21.18 | 21.754 | 21.754 | 15.887 | 15.887 |
| General & Administrative Expenses
| 28.188 | 28.188 | 24.625 | 24.625 | 20.789 | 20.789 | 19.415 | 19.415 | 20.328 | 20.328 | 14.429 | 14.429 | 14.792 | 14.792 | 11.368 | 11.368 |
| Selling & Marketing Expenses
| 74.097 | 74.097 | 79.794 | 79.794 | 97.538 | 97.538 | 82.743 | 82.743 | 73.342 | 73.342 | 67.779 | 67.779 | 68.452 | 68.452 | 55.809 | 55.809 |
| SG&A
| 102.285 | 102.285 | 104.419 | 104.419 | 118.327 | 118.327 | 102.158 | 102.158 | 93.669 | 93.669 | 82.208 | 82.208 | 83.244 | 83.244 | 67.177 | 67.177 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 125.66 | 125.66 | 116.184 | 116.184 | 161.815 | 161.815 | 124.563 | 124.563 | 108.713 | 108.713 | 867.591 | 867.591 | 562.416 | 562.416 | 148.951 | 148.951 |
| Operating Income
| -26.379 | -26.379 | -15.615 | -15.615 | 1.691 | 1.691 | 11.907 | 11.907 | 6.149 | 6.149 | 7.915 | 7.915 | 17.706 | 17.706 | 17.644 | 17.644 |
| Operating Income Ratio
| -0.111 | -0.111 | -0.063 | -0.063 | 0.005 | 0.005 | 0.036 | 0.036 | 0.025 | 0.025 | 0.036 | 0.036 | 0.077 | 0.077 | 0.082 | 0.082 |
| Total Other Income Expenses Net
| 24.69 | 24.69 | 38.965 | 38.965 | 3.602 | 3.602 | 24.459 | 24.459 | 16.231 | 16.231 | -757.289 | -757.289 | -456.437 | -456.437 | -60.09 | -60.09 |
| Income Before Tax
| -1.689 | -1.689 | 23.35 | 23.35 | 5.293 | 5.293 | 36.366 | 36.366 | 22.38 | 22.38 | -749.374 | -749.374 | -438.731 | -438.731 | -42.446 | -42.446 |
| Income Before Tax Ratio
| -0.007 | -0.007 | 0.095 | 0.095 | 0.015 | 0.015 | 0.11 | 0.11 | 0.091 | 0.091 | -3.42 | -3.42 | -1.9 | -1.9 | -0.198 | -0.198 |
| Income Tax Expense
| 1.832 | 1.832 | 1.606 | 1.606 | 1.835 | 1.835 | 4.751 | 4.751 | 0.182 | 0.182 | 0.305 | 0.305 | 0.913 | 0.913 | 2.971 | 2.971 |
| Net Income
| -1.348 | -1.348 | 21.991 | 21.991 | 6.461 | 6.461 | 31.268 | 31.268 | 23.636 | 23.636 | -750.851 | -750.851 | -440.907 | -440.907 | -46.104 | -46.104 |
| Net Income Ratio
| -0.006 | -0.006 | 0.089 | 0.089 | 0.018 | 0.018 | 0.095 | 0.095 | 0.096 | 0.096 | -3.427 | -3.427 | -1.909 | -1.909 | -0.215 | -0.215 |
| EPS
| -0.004 | -0.004 | 0.023 | 0.023 | 0.01 | 0.01 | 0.03 | 0.03 | 0.028 | 0.028 | -5.17 | -5.17 | -3.76 | -3.76 | -0.43 | -0.43 |
| EPS Diluted
| -0.001 | -0.001 | 0.023 | 0.023 | 0.01 | 0.01 | 0.031 | 0.031 | 0.028 | 0.028 | -5.17 | -5.17 | -3.76 | -3.76 | -0.43 | -0.43 |
| EBITDA
| -15.031 | -15.031 | -1.799 | -1.799 | 13.358 | 13.358 | 24.389 | 24.389 | 14.35 | 14.35 | 17.575 | 17.575 | 24.971 | 24.971 | 27.615 | 27.615 |
| EBITDA Ratio
| -0.063 | -0.063 | -0.007 | -0.007 | 0.037 | 0.037 | 0.074 | 0.074 | 0.058 | 0.058 | 0.08 | 0.08 | 0.108 | 0.108 | 0.129 | 0.129 |